BioMedNewsBreaks – Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) Closes on $3M Convertible Note Led by Rapha Capital

Imagin Medical (CSE: IME) (OTCQB: IMEXF), a surgical imaging company focused on advancing new methods of visualizing cancer during minimally invasive procedures, has announced that Rapha Capital BioVentures Fund I, LP (“RCBVFI”) led and closed on a new convertible note offering totaling $3 million. The note, which was funded in three tranches, will support the clinical development of Imagin Medical’s flagship product: the i/Blue(TM) Imaging System. In addition, RCBVFI manager and leading urooncologist Dr. Kevin Slawin, MD, was appointed to Imagin’s board of directors, and Imagin also announced an updated website that features the company’s new logo and reflects the company’s change in energy, focus and direction. In addition to the closing of the note, the announcement noted that Rapha Capital can appoint a second board member upon closing of at least $1 million. Rapha Capital will also receive warrants to acquire shares of Imagin and will be granted a preemptive right to participate in any future financing started by Imagin. “As a urologist who cared for patients with cancer over a 25-year career as a professor and urological oncologic surgeon, I have a deep knowledge of the field and of the needs of patients with prostate and bladder cancer,” said RCBVFI manager and Imagin Medical’s newest board member Dr. Kevin Slawin in the press release. “Taking the lead investor role in Imagin signifies my appreciation of Imagin’s advanced i/Blue Imaging Systemand the potential it may bring to the improvement in the care of these patients. Our investment will enable us to bring this lead product through the FDA submission process over the next year.”

To view the full press release, visit https://ibn.fm/T6BWf

About Imagin Medical 

Imagin Medical is a surgical imaging company focused on advancing new methods of visualizing cancer during minimally invasive procedures. The company believes its first product, the i/Blue Imaging System, with its proprietary optics and light sensors, will greatly increase the efficiency and accuracy of detecting cancer for removal, helping to reduce recurrence rates. The company’s initial focus is bladder cancer. For more information about the company, visit www.ImaginMedical.com.

NOTE TO INVESTORS: The latest news and updates relating to IMEXF are available in the company’s newsroom at https://ibn.fm/IMEXF

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork